Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
209 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hyperlipidemia - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Hyperlipidemia - Pipeline Review, H2 2016', provides an overview of the Hyperlipidemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia - The report reviews pipeline therapeutics for Hyperlipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hyperlipidemia therapeutics and enlists all their major and minor projects - The report assesses Hyperlipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hyperlipidemia Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hyperlipidemia Overview 9 Therapeutics Development 10 Pipeline Products for Hyperlipidemia - Overview 10 Pipeline Products for Hyperlipidemia - Comparative Analysis 11 Hyperlipidemia - Therapeutics under Development by Companies 12 Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 16 Hyperlipidemia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Hyperlipidemia - Products under Development by Companies 21 Hyperlipidemia - Products under Investigation by Universities/Institutes 24 Hyperlipidemia - Companies Involved in Therapeutics Development 25 Acasti Pharma Inc. 25 Akcea Therapeutics Inc 26 Allergan Plc 27 Alnylam Pharmaceuticals, Inc. 28 Amgen Inc. 29 Arisaph Pharmaceuticals, Inc. 30 AstraZeneca Plc 31 BASF SE 32 BCWorld Pharm Co. Ltd. 33 BioRestorative Therapies, Inc. 34 Cadila Pharmaceuticals Limited 35 Cardax Pharmaceuticals, Inc. 36 Catabasis Pharmaceuticals, Inc. 37 CJ HealthCare Corp. 38 CymaBay Therapeutics, Inc. 39 Daewoong Pharmaceutical Co., Ltd. 40 Esperion Therapeutics, Inc. 41 Golden Biotechnology Corp. 42 HanAll Biopharma Co., Ltd. 43 Hanmi Pharmaceuticals, Co. Ltd. 44 Huons Co., Ltd. 45 Hyundai Pharmaceutical Co., Ltd. 46 Innovent Biologics, Inc. 47 Jeil Pharmaceutical Co., Ltd. 48 Kowa Company, Ltd. 49 Kyorin Pharmaceutical Co., Ltd. 50 LG Life Science LTD. 51 LipimetiX Development Inc 52 Matinas BioPharma Holdings, Inc. 53 Pfizer Inc. 54 Pharmena SA 55 Protalix BioTherapeutics, Inc. 56 Regeneron Pharmaceuticals Inc 57 Sancilio & Company, Inc. 58 Yuhan Corporation 59 Zydus Cadila Healthcare Limited 60 Hyperlipidemia - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Combination Products 62 Assessment by Target 63 Assessment by Mechanism of Action 67 Assessment by Route of Administration 71 Assessment by Molecule Type 73 Drug Profiles 75 (amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile 75 (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 76 (atorvastatin calcium + losartan potassium) - Drug Profile 77 (atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 78 (ezetimibe + rosuvastatin calcium) - Drug Profile 79 (gemigliptin + rosuvastatin calcium) - Drug Profile 80 (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 81 AC-261066 - Drug Profile 82 AEM-28 - Drug Profile 83 AEM-2802 - Drug Profile 85 AEM-2814 - Drug Profile 86 ALN-AC3 - Drug Profile 87 ALN-ANG - Drug Profile 88 antroquinonol - Drug Profile 89 ARI-3037MO - Drug Profile 91 BCWPC-001 - Drug Profile 93 bempedoic acid - Drug Profile 94 bezafibrate ER - Drug Profile 102 BH-03004 - Drug Profile 103 BioE-1115 - Drug Profile 104 bococizumab - Drug Profile 105 BSN-272 - Drug Profile 109 CAT-2000 Series - Drug Profile 110 CAT-2003 - Drug Profile 111 CDX-085 - Drug Profile 114 centatin - Drug Profile 116 DWJ-1351 - Drug Profile 117 etanercept biosimilar - Drug Profile 118 evolocumab - Drug Profile 120 gemcabene calcium - Drug Profile 132 HOB-071 - Drug Profile 134 HU-012 - Drug Profile 135 IBI-306 - Drug Profile 136 icosabutate - Drug Profile 137 IMMH-007 - Drug Profile 138 ISIS-APOCIIILRx - Drug Profile 139 JS-002 - Drug Profile 140 K-312 - Drug Profile 141 leucine + niacin - Drug Profile 142 LTPO-3FA - Drug Profile 143 MAT-9001 - Drug Profile 144 MBX-8025 - Drug Profile 146 MN-002 - Drug Profile 149 NKPL-66 - Drug Profile 150 Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 154 omega-3-carboxylic acids - Drug Profile 155 PF-06427878 - Drug Profile 159 PF-06815345 - Drug Profile 160 Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 161 REGN-1001 - Drug Profile 162 saroglitazar - Drug Profile 163 SC-401 - Drug Profile 165 Small Molecule for Atherosclerosis and Hyperlipidemia - Drug Profile 166 Small Molecule for Hyperlipidemia - Drug Profile 167 Small Molecule for Hypertriglyceridaemia - Drug Profile 168 Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile 169 Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes - Drug Profile 170 Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 172 TRIA-662 - Drug Profile 173 volanesorsen sodium - Drug Profile 175 YH-22189 - Drug Profile 181 Hyperlipidemia - Dormant Projects 182 Hyperlipidemia - Discontinued Products 191 Hyperlipidemia - Product Development Milestones 192 Featured News & Press Releases 192 Appendix 204 Methodology 204 Coverage 204 Secondary Research 204 Primary Research 204 Expert Panel Validation 204 Contact Us 204 Disclaimer 205
List of Tables
Number of Products under Development for Hyperlipidemia, H2 2016 14 Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Comparative Analysis by Unknown Stage Development, H2 2016 24 Products under Development by Companies, H2 2016 25 Products under Development by Companies, H2 2016 (Contd..1) 26 Products under Development by Companies, H2 2016 (Contd..2) 27 Products under Investigation by Universities/Institutes, H2 2016 28 Hyperlipidemia - Pipeline by Acasti Pharma Inc., H2 2016 29 Hyperlipidemia - Pipeline by Akcea Therapeutics Inc, H2 2016 30 Hyperlipidemia - Pipeline by Allergan Plc, H2 2016 31 Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 32 Hyperlipidemia - Pipeline by Amgen Inc., H2 2016 33 Hyperlipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 34 Hyperlipidemia - Pipeline by AstraZeneca Plc, H2 2016 35 Hyperlipidemia - Pipeline by BASF SE, H2 2016 36 Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016 37 Hyperlipidemia - Pipeline by BioRestorative Therapies, Inc., H2 2016 38 Hyperlipidemia - Pipeline by Cadila Pharmaceuticals Limited, H2 2016 39 Hyperlipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016 40 Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 41 Hyperlipidemia - Pipeline by CJ HealthCare Corp., H2 2016 42 Hyperlipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016 43 Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 44 Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H2 2016 45 Hyperlipidemia - Pipeline by Golden Biotechnology Corp., H2 2016 46 Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 47 Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 48 Hyperlipidemia - Pipeline by Huons Co., Ltd., H2 2016 49 Hyperlipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 50 Hyperlipidemia - Pipeline by Innovent Biologics, Inc., H2 2016 51 Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 52 Hyperlipidemia - Pipeline by Kowa Company, Ltd., H2 2016 53 Hyperlipidemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 54 Hyperlipidemia - Pipeline by LG Life Science LTD., H2 2016 55 Hyperlipidemia - Pipeline by LipimetiX Development Inc, H2 2016 56 Hyperlipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 57 Hyperlipidemia - Pipeline by Pfizer Inc., H2 2016 58 Hyperlipidemia - Pipeline by Pharmena SA, H2 2016 59 Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 60 Hyperlipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 61 Hyperlipidemia - Pipeline by Sancilio & Company, Inc., H2 2016 62 Hyperlipidemia - Pipeline by Yuhan Corporation, H2 2016 63 Hyperlipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 64 Assessment by Monotherapy Products, H2 2016 65 Assessment by Combination Products, H2 2016 66 Number of Products by Stage and Target, H2 2016 68 Number of Products by Stage and Mechanism of Action, H2 2016 72 Number of Products by Stage and Route of Administration, H2 2016 76 Number of Products by Stage and Molecule Type, H2 2016 78 Hyperlipidemia - Dormant Projects, H2 2016 186 Hyperlipidemia - Dormant Projects (Contd..1), H2 2016 187 Hyperlipidemia - Dormant Projects (Contd..2), H2 2016 188 Hyperlipidemia - Dormant Projects (Contd..3), H2 2016 189 Hyperlipidemia - Dormant Projects (Contd..4), H2 2016 190 Hyperlipidemia - Dormant Projects (Contd..5), H2 2016 191 Hyperlipidemia - Dormant Projects (Contd..6), H2 2016 192 Hyperlipidemia - Dormant Projects (Contd..7), H2 2016 193 Hyperlipidemia - Dormant Projects (Contd..8), H2 2016 194 Hyperlipidemia - Discontinued Products, H2 2016 195
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.